Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

GSK Braces For Impact: Advair Generic Could Reduce US Brand To £1Bn

Executive Summary

Although it’s not yet clear if an interchangeable version of the respiratory blockbuster will be approved by FDA, CEO Andrew Witty prepared investors to expect a hit, forecasting that a mid-year launch could significantly reduce revenues.

Advertisement

Related Content

Stockwatch: Flat Is The New Black For Lilly And Sanofi
Teva AirDuo Poised To Be A Discounted, But Not Interchangeable, Version Of Advair
GSK US Pharma President Jack Bailey On A “Dynamic” 2017
Advair: A Big Generic Opportunity And A Big Question Mark In 2017

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register